Table 2.

Outcome studies with different inhibition of platelet aggregation

Study	Study patients	Clopidogrel dose	Platelet function assay	Platelet reactivity measure	End-point prediction
Matetzky et al6	STEMI-PCI patients: 60	300 mg post-PCI	LTA (ADP induced aggregation)	Patients stratified into 4 quartiles	MACE at 6 months P < 0.01
Gurbel et al60	ELLECTIVE PCI, patients: 192	300/600 mg post PCI	LTA and TEG	Patients stratified in different quartiles	MACE at 6 months P = 0.02
Bliden et al61	ELLECTIVE PCI, patients: 100	75 mg for >1 month	LTA and TEG	Pre-procedural platelet aggregation in patients on clopidogrel	MACE at 12 months P < 0.001
Bonello et al38	ELLECTIVE PCI, patients: 144	300 mg, 24 hours prior to PCI	VASP-P	PRI > 50%	MACE at 6 months P < 0.01
Price et al63	ELLECTIVE PCI, patients: 380	600 mg, 12 hours prior to PCI	VerifyNow	PRU > 235	MACE at 6 months P = 0.008
Marcucci et al64	ACS-PCI patients: 683	600 mg prior to PCI	VerifyNow	PRU > 240	MACE at 12 months CV death P = 0.034 MI P = 0.004
Migliorini et al62	PCI unprotected LM, patients: 215	600 mg prior to PCI	LTA	Platelet reactivity > 70%	MACE at 19.3 months P = 0.005
El Ghannudi et al65	ELECTIVE and URGENT PCI, patients: 461	300 or 600 mg	VASP-P	PRI > 61%	MACE at 9 months P = 0.037
Breet et al66	ELLECTIVE PCI, patients: 1069	75 mg >5 days or 300 mg >24 hours prior or 600 mg >4 hours prior to PCI	LTA, VerifyNow, plateletworks, IMPACT, Innovance PFA and PFA-100	Standard Platelet function measurement values	MACE at 12 months P values for tests shown in Figure 2

Abbreviations: ADP, adenosine diphosphate; LM, left main; LTA, light transmittance aggregometry; CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial infarction; PFA, platelet function assay; PRI, platelet reactivity index; PRU, P2Y12 reaction unit; TEG, thrombelastography; VASP-P, vasodilator-stimulated phosphoprotein phosphorylation.